Metagenomi, Inc. Common Stock (MGX) - Total Liabilities
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has total liabilities worth $61.13 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Metagenomi, Inc. Common Stock (MGX) investment intensity to see how much of total assets are deployed in long-term investments.
Metagenomi, Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Metagenomi, Inc. Common Stock asset portfolio.
Metagenomi, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Econpile Holdings Bhd
KLSE:5253
|
Malaysia | RM247.59 Million |
|
Reading International Inc
NASDAQ:RDI
|
USA | $456.87 Million |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$18.99 Million |
|
Mudajaya Group Bhd
KLSE:5085
|
Malaysia | RM1.14 Billion |
|
HS Valve Co. Ltd
KQ:039610
|
Korea | ₩37.23 Billion |
|
Theralase Technologies Inc.
V:TLT
|
Canada | CA$1.28 Million |
|
Rompetrol Well
RO:PTR
|
Romania | RON20.74 Million |
|
SKILLCAST GROUP LS -001
F:K9I
|
Germany | €9.15 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Metagenomi, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Metagenomi, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Metagenomi, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Metagenomi, Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $62.51 Million | -30.35% |
| 2024-09-30 | $89.74 Million | -82.07% |
| 2023-09-30 | $500.43 Million | +2.35% |
| 2022-09-30 | $488.91 Million | +180.12% |
| 2021-09-30 | $174.54 Million | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more